


LCC

LIVERPOOL CHIROCHEM

Molecule of the Month

ASTX660



For this month's MOTM we are going to highlight ASTX660.

Currently in phase 1/2 clinical trials in cancer patients. Developed by ASTEX Pharmaceuticals as a potent non-peptidic antagonist of X-linked inhibitor of apoptosis protein (XIAP) and inhibitor of apoptosis proteins (IAPs). Antagonists of these proteins have the potential to switch pro-survival signalling pathways in cancer cells toward cell death (Mol Cancer Ther. 2018, 1381-1391).

Should you require analogues of these molecules to support your research activities don't hesitate to get in touch with us. Alternatively, if you would like to explore our complete range of products and services or require any further information regarding LCC, please use the enquiry button at the top of our webpage to get in touch.

